Cargando…
Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
BACKGROUND: Numerous efficacious chemotherapy regimens may cause thrombocytopenia. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of chemotherapy-induced thrombocytopenia. The TPO-R MPL is expressed on megakaryocytes and megakaryocyte prec...
Autores principales: | Erickson-Miller, Connie L, Pillarisetti, Kodandaram, Kirchner, Jennifer, Figueroa, David J, Ottesen, Lone, Martin, Anne-Marie, Liu, Yuan, Kamel, Yasser Mostafa, Messam, Conrad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480928/ https://www.ncbi.nlm.nih.gov/pubmed/22967017 http://dx.doi.org/10.1186/1471-2407-12-405 |
Ejemplares similares
-
Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors
por: Erickson-Miller, Connie L., et al.
Publicado: (2010) -
Lnk Inhibits Tpo–mpl Signaling and Tpo-mediated Megakaryocytopoiesis
por: Tong, Wei, et al.
Publicado: (2004) -
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
por: Chawla, Sant P, et al.
Publicado: (2013) -
Cryo-electron microscopy structures of human thyroid peroxidase (TPO) in complex with TPO antibodies
por: Baker, Stuart, et al.
Publicado: (2022) -
TPO/Mpl Studies in Agnogenic Myeloid Metaplasia
por: Hemavathy, Kirugaval C, et al.
Publicado: (2005)